{
    "Trade/Device Name(s)": [
        "FRENDTM TSH"
    ],
    "Submitter Information": "NanoEnTek, Inc.",
    "510(k) Number": "K131928",
    "Predicate Device Reference 510(k) Number(s)": [
        "K972586"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JLW"
    ],
    "Summary Letter Date": "March 14, 2014",
    "Summary Letter Received Date": "February 7, 2014",
    "Submission Date": "February 4, 2014",
    "Regulation Number(s)": [
        "21 CFR 862.1690"
    ],
    "Regulation Name(s)": [
        "Thyroid stimulating hormone test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Thyroid Stimulating Hormone (TSH)",
        "Thyrotropin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "FREND \u2122 system",
        "FREND \u2122M system"
    ],
    "Method(s)/Technology(ies)": [
        "Fluorescent immunoassay"
    ],
    "Methodologies": [
        "Quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for NanoEnTek FRENDTM TSH quantitative fluorescent immunoassay for thyroid stimulating hormone measurement using the FREND system",
    "Indications for Use Summary": "Designed for in vitro diagnostic use for quantitative measurement of thyroid stimulating hormone (TSH) in human serum and lithium heparin plasma using the FREND system as an aid in the diagnosis of thyroid disease in clinical laboratories upon physician prescription.",
    "fda_folder": "Clinical Chemistry"
}